MeiraGTx Holdings PLC (NASDAQ:MGTX – Get Free Report) CEO Alexandria Forbes sold 62,000 shares of MeiraGTx stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $8.45, for a total value of $523,900.00. Following the completion of the sale, the chief executive officer owned 1,239,595 shares in the company, valued at approximately $10,474,577.75. The trade was a 4.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
MeiraGTx Price Performance
NASDAQ:MGTX opened at $8.13 on Friday. The stock has a 50 day moving average of $10.31 and a two-hundred day moving average of $10.38. MeiraGTx Holdings PLC has a 12 month low of $6.62 and a 12 month high of $15.35. The firm has a market cap of $794.54 million, a P/E ratio of 10.16 and a beta of 1.09. The company has a current ratio of 4.62, a quick ratio of 4.62 and a debt-to-equity ratio of 0.57.
MeiraGTx (NASDAQ:MGTX – Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.03). The firm had revenue of $4.81 million during the quarter, compared to analysts’ expectations of $6.95 million. MeiraGTx had a net margin of 19.46% and a return on equity of 85.23%. On average, analysts expect that MeiraGTx Holdings PLC will post 0.20 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. Rubric Capital Management LP raised its holdings in MeiraGTx by 13.4% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company’s stock worth $60,620,000 after purchasing an additional 824,669 shares during the last quarter. Johnson & Johnson bought a new stake in shares of MeiraGTx in the 2nd quarter worth $89,720,775. BlackRock Inc. bought a new stake in shares of MeiraGTx during the 2nd quarter worth $64,269,000. Opaleye Management Inc. raised its holdings in MeiraGTx by 67.2% in the second quarter. Opaleye Management Inc. now owns 3,550,000 shares of the company’s stock worth $47,960,000 after purchasing an additional 1,426,741 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of MeiraGTx by 250.3% during the third quarter. Goldman Sachs Group Inc. now owns 1,147,015 shares of the company’s stock valued at $12,617,000 after purchasing an additional 819,599 shares during the last quarter. 67.48% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
MGTX has been the subject of a number of recent analyst reports. The Goldman Sachs Group began coverage on shares of MeiraGTx in a report on Thursday, September 24th. They set a “neutral” rating and a $16.00 price target for the company. Zacks Research cut MeiraGTx from a “strong-buy” rating to a “hold” rating in a report on Friday, September 11th. Weiss Ratings downgraded MeiraGTx from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, November 13th. Wall Street Zen downgraded MeiraGTx from a “buy” rating to a “hold” rating in a research report on Saturday, November 14th. Finally, Royal Bank Of Canada boosted their price target on MeiraGTx from $26.00 to $27.00 and gave the stock an “outperform” rating in a report on Friday, August 14th. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, MeiraGTx has an average rating of “Moderate Buy” and a consensus price target of $24.00.
Read Our Latest Report on MGTX
MeiraGTx Company Profile
MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.
Featured Articles
- Five stocks we like better than MeiraGTx
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
